Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.

Summary Expression Phenotypes Gene Literature (71) GO Terms (6) Nucleotides (57) Proteins (36) Interactants (59) Wiki
XB-GENEPAGE-6035308

Papers associated with p2rx1



???displayGene.coCitedPapers???

???pagination.result.count???

???pagination.result.page??? 1 2 ???pagination.result.next???

Sort Newest To Oldest Sort Oldest To Newest

Dopamine and 5-hydroxytryptamine selectively potentiate neuronal type ATP receptor channels., Nakazawa K, Ohno Y., Eur J Pharmacol. January 18, 1996; 296 (1): 119-22.

Domains of P2X receptors involved in desensitization., Werner P, Seward EP, Buell GN, North RA., Proc Natl Acad Sci U S A. December 24, 1996; 93 (26): 15485-90.

Neuropharmacology: a part for purines in pattern generation., Halliday FC, Gibb AJ., Curr Biol. January 1, 1997; 7 (1): R47-9.

Effects of neuroamines and divalent cations on cloned and mutated ATP-gated channels., Nakazawa K, Ohno Y., Eur J Pharmacol. April 23, 1997; 325 (1): 101-8.

Potent inhibition by trivalent cations of ATP-gated channels., Nakazawa K, Liu M, Inoue K, Ohno Y., Eur J Pharmacol. May 1, 1997; 325 (2-3): 237-43.

P2X1 and P2X3 receptors form stable trimers: a novel structural motif of ligand-gated ion channels., Nicke A, Bäumert HG, Rettinger J, Eichele A, Lambrecht G, Mutschler E, Schmalzing G., EMBO J. June 1, 1998; 17 (11): 3016-28.

A pyridoxine cyclic phosphate and its 6-azoaryl derivative selectively potentiate and antagonize activation of P2X1 receptors., Jacobson KA, Kim YC, Wildman SS, Mohanram A, Harden TK, Boyer JL, King BF, Burnstock G., J Med Chem. June 18, 1998; 41 (13): 2201-6.

Antagonistic properties of the suramin analogue NF023 at heterologously expressed P2X receptors., Soto F, Lambrecht G, Nickel P, Stühmer W, Busch AE., Neuropharmacology. January 1, 1999; 38 (1): 141-9.

Selectivity of diadenosine polyphosphates for rat P2X receptor subunits., Wildman SS, Brown SG, King BF, Burnstock G., Eur J Pharmacol. February 12, 1999; 367 (1): 119-23.

Functional and biochemical evidence for heteromeric ATP-gated channels composed of P2X1 and P2X5 subunits., Lê KT, Boué-Grabot E, Archambault V, Séguéla P., J Biol Chem. May 28, 1999; 274 (22): 15415-9.

Modulatory activity of extracellular H+ and Zn2+ on ATP-responses at rP2X1 and rP2X3 receptors., Wildman SS, King BF, Burnstock G., Br J Pharmacol. September 1, 1999; 128 (2): 486-92.

Diinosine pentaphosphate (IP5I) is a potent antagonist at recombinant rat P2X1 receptors., King BF, Liu M, Pintor J, Gualix J, Miras-Portugal MT, Burnstock G., Br J Pharmacol. November 1, 1999; 128 (5): 981-8.

A natural dominant negative P2X1 receptor due to deletion of a single amino acid residue., Oury C, Toth-Zsamboki E, Van Geet C, Thys C, Wei L, Nilius B, Vermylen J, Hoylaerts MF., J Biol Chem. July 28, 2000; 275 (30): 22611-4.

Roles of individual N-glycans for ATP potency and expression of the rat P2X1 receptor., Rettinger J, Aschrafi A, Schmalzing G., J Biol Chem. October 27, 2000; 275 (43): 33542-7.

Platelets and P2X1: is ADP really an agonist?, Jarvis G., Trends Pharmacol Sci. November 1, 2000; 21 (11): 421.

Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors., Kim YC, Brown SG, Harden TK, Boyer JL, Dubyak G, King BF, Burnstock G, Jacobson KA., J Med Chem. February 1, 2001; 44 (3): 340-9.

Actions of a Series of PPADS Analogs at P2X1 and P2X3 Receptors., Brown SG, Kim YC, Kim SA, Jacobson KA, Burnstock G, King BF., Drug Dev Res. August 1, 2001; 53 (4): 281-291.

NF449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors., Braun K, Rettinger J, Ganso M, Kassack M, Hildebrandt C, Ullmann H, Nickel P, Schmalzing G, Lambrecht G., Naunyn Schmiedebergs Arch Pharmacol. September 1, 2001; 364 (3): 285-90.

Selective agonism of group I P2X receptors by dinucleotides dependent on a single adenine moiety., Cinkilic O, King BF, van der Giet M, Schlüter H, Zidek W, Burnstock G., J Pharmacol Exp Ther. October 1, 2001; 299 (1): 131-6.

The ATP-gated P2X1 ion channel acts as a positive regulator of platelet responses to collagen., Oury C, Toth-Zsamboki E, Thys C, Tytgat J, Vermylen J, Hoylaerts MF., Thromb Haemost. November 1, 2001; 86 (5): 1264-71.

Monomeric and dimeric byproducts are the principal functional elements of higher order P2X1 concatamers., Nicke A, Rettinger J, Schmalzing G., Mol Pharmacol. January 1, 2003; 63 (1): 243-52.

Activation and desensitization of the recombinant P2X1 receptor at nanomolar ATP concentrations., Rettinger J, Schmalzing G., J Gen Physiol. May 1, 2003; 121 (5): 451-61.          

NF449, a novel picomolar potency antagonist at human P2X1 receptors., Hülsmann M, Nickel P, Kassack M, Schmalzing G, Lambrecht G, Markwardt F., Eur J Pharmacol. May 30, 2003; 470 (1-2): 1-7.

Dissecting individual current components of co-expressed human P2X1 and P2X7 receptors., Seyffert C, Schmalzing G, Markwardt F., Curr Top Med Chem. January 1, 2004; 4 (16): 1719-30.

Desensitization masks nanomolar potency of ATP for the P2X1 receptor., Rettinger J, Schmalzing G., J Biol Chem. February 20, 2004; 279 (8): 6426-33.

ATP binding at human P2X1 receptors. Contribution of aromatic and basic amino acids revealed using mutagenesis and partial agonists., Roberts JA, Evans RJ., J Biol Chem. March 5, 2004; 279 (10): 9043-55.

G-protein-coupled receptor regulation of P2X1 receptors does not involve direct channel phosphorylation., Vial C, Tobin AB, Evans RJ., Biochem J. August 15, 2004; 382 (Pt 1): 101-10.

Trimeric architecture of homomeric P2X2 and heteromeric P2X1+2 receptor subtypes., Aschrafi A, Sadtler S, Niculescu C, Rettinger J, Schmalzing G., J Mol Biol. September 3, 2004; 342 (1): 333-43.

Biochemical and functional evidence for heteromeric assembly of P2X1 and P2X4 subunits., Nicke A, Kerschensteiner D, Soto F., J Neurochem. February 1, 2005; 92 (4): 925-33.

Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analogue NF449 as a highly potent P2X1 receptor antagonist., Rettinger J, Braun K, Hochmann H, Kassack MU, Ullmann H, Nickel P, Schmalzing G, Lambrecht G., Neuropharmacology. March 1, 2005; 48 (3): 461-8.

Mutagenesis studies of conserved proline residues of human P2X receptors for ATP indicate that proline 272 contributes to channel function., Roberts JA, Evans RJ., J Neurochem. March 1, 2005; 92 (5): 1256-64.

Inhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF449 [4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis-(carbonylimino)))tetrakis-benzene-1,3-disulfonic acid octasodium salt]., Hechler B, Magnenat S, Zighetti ML, Kassack MU, Ullmann H, Cazenave JP, Evans R, Cattaneo M, Gachet C., J Pharmacol Exp Ther. July 1, 2005; 314 (1): 232-43.

Regulatory interdependence of cloned epithelial Na+ channels and P2X receptors., Wildman SS, Marks J, Churchill LJ, Peppiatt CM, Chraibi A, Shirley DG, Horisberger JD, King BF, Unwin RJ., J Am Soc Nephrol. September 1, 2005; 16 (9): 2586-97.

Potentiation of P2X1 ATP-gated currents by 5-hydroxytryptamine 2A receptors involves diacylglycerol-dependent kinases and intracellular calcium., Ase AR, Raouf R, Bélanger D, Hamel E, Séguéla P., J Pharmacol Exp Ther. October 1, 2005; 315 (1): 144-54.

Contribution of conserved glycine residues to ATP action at human P2X1 receptors: mutagenesis indicates that the glycine at position 250 is important for channel function., Digby HR, Roberts JA, Sutcliffe MJ, Evans RJ., J Neurochem. December 1, 2005; 95 (6): 1746-54.

Contribution of conserved polar glutamine, asparagine and threonine residues and glycosylation to agonist action at human P2X1 receptors for ATP., Roberts JA, Evans RJ., J Neurochem. February 1, 2006; 96 (3): 843-52.

Contribution of P2X1 receptor intracellular basic residues to channel properties., Vial C, Rigby R, Evans RJ., Biochem Biophys Res Commun. November 10, 2006; 350 (1): 244-8.

Identification of an intersubunit cross-link between substituted cysteine residues located in the putative ATP binding site of the P2X1 receptor., Marquez-Klaka B, Rettinger J, Bhargava Y, Eisele T, Nicke A., J Neurosci. February 7, 2007; 27 (6): 1456-66.

Cysteine substitution mutants give structural insight and identify ATP binding and activation sites at P2X receptors., Roberts JA, Evans RJ., J Neurosci. April 11, 2007; 27 (15): 4072-82.

Lack of evidence for direct phosphorylation of recombinantly expressed P2X(2) and P2X (3) receptors by protein kinase C., Franklin C, Braam U, Eisele T, Schmalzing G, Hausmann R., Purinergic Signal. September 1, 2007; 3 (4): 377-88.              

Cysteine substitution mutagenesis and the effects of methanethiosulfonate reagents at P2X2 and P2X4 receptors support a core common mode of ATP action at P2X receptors., Roberts JA, Digby HR, Kara M, El Ajouz S, Sutcliffe MJ, Evans RJ., J Biol Chem. July 18, 2008; 283 (29): 20126-36.                

Direct modulation of P2X1 receptor-channels by the lipid phosphatidylinositol 4,5-bisphosphate., Bernier LP, Ase AR, Tong X, Hamel E, Blais D, Zhao Q, Logothetis DE, Séguéla P., Mol Pharmacol. September 1, 2008; 74 (3): 785-92.

Regions of the amino terminus of the P2X receptor required for modification by phorbol ester and mGluR1alpha receptors., Wen H, Evans RJ., J Neurochem. January 1, 2009; 108 (2): 331-40.            

A P2X receptor from the tardigrade species Hypsibius dujardini with fast kinetics and sensitivity to zinc and copper., Bavan S, Straub VA, Blaxter ML, Ennion SJ., BMC Evol Biol. January 20, 2009; 9 17.            

Contribution of the region Glu181 to Val200 of the extracellular loop of the human P2X1 receptor to agonist binding and gating revealed using cysteine scanning mutagenesis., Roberts JA, Valente M, Allsopp RC, Watt D, Evans RJ., J Neurochem. May 1, 2009; 109 (4): 1042-52.              

Selective potentiation of homomeric P2X2 ionotropic ATP receptors by a fast non-genomic action of progesterone., De Roo M, Boué-Grabot E, Schlichter R., Neuropharmacology. March 1, 2010; 58 (3): 569-77.

Amino acid residues constituting the agonist binding site of the human P2X3 receptor., Bodnar M, Wang H, Riedel T, Hintze S, Kato E, Fallah G, Gröger-Arndt H, Giniatullin R, Grohmann M, Hausmann R, Schmalzing G, Illes P, Rubini P., J Biol Chem. January 28, 2011; 286 (4): 2739-49.

Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor., Baqi Y, Hausmann R, Rosefort C, Rettinger J, Schmalzing G, Müller CE., J Med Chem. February 10, 2011; 54 (3): 817-30.

Contribution of the intracellular C terminal domain to regulation of human P2X1 receptors for ATP by phorbol ester and Gq coupled mGlu(1α) receptors., Wen H, Evans RJ., Eur J Pharmacol. March 5, 2011; 654 (2): 155-9.        

Cysteine scanning mutagenesis (residues Glu52-Gly96) of the human P2X1 receptor for ATP: mapping agonist binding and channel gating., Allsopp RC, El Ajouz S, Schmid R, Evans RJ., J Biol Chem. August 19, 2011; 286 (33): 29207-17.              

???pagination.result.page??? 1 2 ???pagination.result.next???